????Publication News: A letter to the editor in Taylor & Francis Group’s Leukemia & Lymphoma highlights key findings from the IMerge Phase 3 clinical trial in lower-risk #MDS.? ? ???https://lnkd.in/dPhzib8G
Geron Corporation
生物技术研究
Foster City，California 13,931 位关注者
Changing lives by changing the course of blood cancer.
关于我们
Geron is a biopharmaceutical company that is charting a new course with the goal to deliver innovative treatment options for people living with blood cancer. Our tireless pursuit to improve outcomes for these patients resulted in the U.S. approval of the first ever telomerase inhibitor for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. As the sole company with an oligonucleotide telomerase inhibitor approved by the FDA, we feel a deep urgency to bring the potential power of telomerase inhibition to patients in need. We are conducting research in other blood cancers with high unmet need beyond LR-MDS, with ongoing clinical trials across other hematologic malignancies, including a pivotal Phase 3 clinical trial in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF). We are proud of the impact this Nobel-winning science is having in the fight against blood cancers. At Geron, we are united by a shared purpose: Every individual in every role can meaningfully contribute to our mission to change lives by changing the course of blood cancer. With a culture rooted in courage and determination, we will continue to innovate and pursue new possibilities for patients. To learn more, visit www.geron.com. Geron’s Community Guidelines: https://www.geron.com/CommunityGuidelines/
- 网站
-
https://www.geron.com
Geron Corporation的外部链接
- 所属行业
- 生物技术研究
- 规模
- 201-500 人
- 总部
- Foster City，California
- 类型
- 上市公司
- 创立
- 1992
- 领域
- Oncology、Hematologic Malignancies和Telomerase Inhibition
地点
-
获取路线
919 E Hillsdale Blvd
US，California，Foster City，94404
Geron Corporation员工
动态
-
????Publication News: A mini-review in ASCPT Journal Family’s Clinical and Translational Science summarizes the mechanism of action, characteristics, clinical development and efficacy, and safety data of a treatment for certain lower-risk #MDS patients. ? ?? https://lnkd.in/eACQXKku
-
-
Meet?Jolinda Schulte, Central Region Business Director. ? Reflecting on her path to Geron, Jolinda shares that it was the Nobel Prize-winning research and Geron’s shared vision that drew her in. "The Geron team’s spirit reinforced my commitment to be a part of this journey," she says.? ? Now, as Central Region Business Director, she finds fulfilment in collaborating with her team and connecting with customers, knowing they are all working together toward the potential for a better quality of life for those affected by #bloodcancer.
-
-
Today, we announced the appointment of?Joseph E. Eid, M.D. as Executive Vice President, Research and Development, to?lead an integrated, cross-functional R&D organization, comprised of our medical, clinical and safety/pharmacovigilance teams.? ? As we continue to invest in our mission to change patients’ lives by changing the course of #bloodcancer,?Dr. Eid brings to Geron an impressive track record of more than two decades of global leadership and expertise, driving drug development, regulatory and?medical affairs success for small and large biopharmaceutical companies.? ? We are thrilled to welcome him to the Geron leadership team! Learn more: https://lnkd.in/eem5_nyu
-
-
Today?we?also announced?up to $375 million in funding with?Royalty Pharma and?Pharmakon Advisors, LP.?We received $250 million in gross proceeds, with access to an additional $125 million in debt.?We believe that the terms reflect?our medicine’s significant commercial potential, confidence in our future growth?and support our mission to change?lives by changing?the course of blood cancer.?Read more:?https://lnkd.in/eVeE9ubP
-
-
We have released our Q3 2024 financial results and recent business highlights, marking our first full quarter as a commercial company following the FDA approval in June of our medicine for certain adults with lower-risk #MDS with transfusion-dependent anemia. Learn more: https://lnkd.in/eRrKJRK5
-
We are pleased to share that six abstracts highlighting new data in myeloid hematologic malignancies?have been accepted for presentation at the?American Society of Hematology?Annual meeting, December 7-10 in?San Diego, California. Learn more:?https://lnkd.in/gGUtkTTy #ASH24?
-
-
We plan to release our?Q3 2024 financial results and business highlights on November 7 at 8 a.m. ET. Learn more: https://lnkd.in/eUYWDs92
-
-
Welcome?Dawn Liu Winn!?So pleased to have you join our growing Geron team.
I am honored to join Geron Corporation and inspired by our mission to change the lives of people living with #bloodcancers. What an exciting and pivotal moment as we launch our first-in-class telomerase inhibitor in the US! We have remote job openings. Come join me and my amazing colleagues to be part of something special! https://lnkd.in/gVkRrX5r
-
Team Geron is honored to support the?MDS Foundation, Inc.?in their fight against myelodysplastic syndromes (#MDS) by joining their movement to help increase awareness and accelerate critical research for this rare?#bloodcancer.?? ? We love coming together for a great cause, and the #MoveForMDS walks provided many opportunities throughout the year to continue to drive positive change for the?MDS community. Thanks to all who gave their time and energy to show up for patients!??